The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Inclusion criteria

• The safety-expansion phase will be open to accrual only for patients with MPN.
• ≥ 18 years of age
• For patients with solid malignancies and lymphoma, radiographically detectable (Either FDG-PET, CT scan/ MRI or Bone Scan) or measurable disease will be required. Measurable disease is defined as at least one measurable lesion ≥ 10 mm on CT scan (15 mm for nodal lesions).
• Prior therapy for advanced malignancy with no current curative option
• Neutrophil count ≥ 1,000/μL, platelet count ≥ 50,000/μL, and hemoglobin ≥ 8 g/dL (Platelet count must be assessed at least 7 days after a prior transfusion, if any)
• Serum bilirubin ≤ 1.5 mg/dL;
• AST and ALT≤ 1.5 × ULN
• Serum creatinine ≤ 1.5 mg/dL or creatinine clearance of ≥ 50 mL/min based on a 24-hour urine collection
• Patients receiving hydroxyurea may continue receiving it for up to 14 days after the start of protocol treatment if WBC >30 x10^9/L.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Patients with HIV/AIDS are allowed on study if they have an undetectable viral load, CD4 > 300 and on stable Highly Active Antiretroviral Therapy (HAART) regimen for 1 month.
• Patients who have been treated for at least two weeks with stable doses of corticosteroids to address conditions unrelated to their malignancy will be allowed to continue this treatment during enrollment on the current trial.
• Patients currently being treated with a gonadotropin-releasing hormone agonist (GnRH agonist), bicalutamide or with bisphosphonates may continue treatment while on clinical trial PU-H71 as long as the treatment has been initiated before the study start. GnRH agonist must have been well tolerated for at least three months.
• Optional participation in the microdose imaging trial, IRB#10-139.
• Signed written informed consent and HIPAA consent.
• PATIENTS WITH MPN must be:
• On ruxolitinib for at least three months and on a stable dose for at least 1 month prior to enrollment and taking at least 5 mg twice daily of ruxolitinib
• Tolerating ruxolitinib but with persistent manifestations of disease (i.e. persistent splenomegaly, abnormal blood counts, persistent constitutional symptoms residual fibrosis in bone marrow (2+ or greater), or measurable allele burden as evidenced of clonal JAK2 or MPL mutation).
• Ruxilitinib treatment requirements will be waived for patients who have failed this treatment in the past or for whom this treatment is otherwise contraindicated

Exclusion criteria

• Ejection fraction < 50%, as determined by echocardiogram or MUGA scan
• Symptomatic brain or CNS metastases. Previously treated and stable CNS disease is allowed.
• Any of the following for the treatment of cancer within 2 weeks of first study treatment: chemotherapy, immunotherapy, experimental therapy or biologic therapy.
• Any major surgical procedure or radiation within 4 weeks of first study treatment
• Active liver disease, including viral or other hepatitis, or cirrhosis
• Pregnancy or lactation
• Active hepatitis or other active infections
• Any other significant medical condition not under control, including any acute coronary syndrome within the past 6 months.
• Patients with a permanent pacemaker
• Patients with a QTcF or QTcB > 480 ms in the baseline EKG
• Systemic corticosteroids (e.g. prednisone ≥ 12.5 mg/day or dexamethasone ≥ 2 mg/day) for the purpose of palliating tumor-related symptoms will not be allowed within 1 week of starting treatment on trial.